Perspective Therapeutics (CATX) 10-Q 13 Feb 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2018	Feb. 11, 2019
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	728,387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		67,331,147
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 3,201	$ 2,600
Short-term investments (Note 3)	4,667	825
Accounts receivable, net	1,107	1,192
Inventory	494	494
Prepaid expenses and other current assets	351	335
Total current assets	9,820	5,446
Property and equipment, net	1,471	1,311
Restricted cash	181	181
Inventory, non-current	266	319
Other assets, net of accumulated amortization	173	198
Total assets	11,911	7,455
Current liabilities:
Accounts payable and accrued expenses	1,196	1,391
Accrued protocol expense	113	77
Accrued radioactive waste disposal	55	37
Accrued payroll and related taxes	120	155
Accrued vacation	156	175
Total current liabilities	1,640	1,835
Long-term liabilities:
Asset retirement obligation	606	590
Total liabilities	2,246	2,425
Commitments and contingencies (Note 8)
Shareholders' equity:
Preferred stock
Common stock, $.001 par value; 200,000,000 shares authorized; 67,331,147 and 56,331,147 shares issued and outstanding	67	56
Additional paid-in capital	91,868	84,322
Accumulated deficit	(82,270)	(79,348)
Total shareholders' equity	9,665	5,030
Total liabilities and shareholders' equity	11,911	7,455
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2018	Jun. 30, 2018
Preferred stock, par value (in dollars per share)		$ 0.001
Preferred stock, shares authorized (in shares)		7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,331,147	56,331,147
Common stock, shares outstanding (in shares)	67,331,147	56,331,147
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Product sales, net	$ 1,904	$ 1,536	$ 3,466	$ 2,747
Cost of product sales	1,139	1,005	2,177	1,951
Gross profit	765	531	1,289	796
Research and development:
Proprietary research and development	395	311	789	597
Collaboration arrangement, net of reimbursement (Note 8)	19	29	45	104
Total research and development	414	340	834	701
Sales and marketing	702	674	1,351	1,288
Gain on equipment disposals	(23)		(23)
General and administrative	1,101	985	2,074	1,827
Total operating expenses	2,194	1,999	4,236	3,816
Operating loss	(1,429)	(1,468)	(2,947)	(3,020)
Non-operating income:
Interest income, net	15	5	25	10
Non-operating income, net	15	5	25	10
Net loss	(1,414)	(1,463)	(2,922)	(3,010)
Preferred stock dividends	(2)	(3)	(5)	(5)
Net loss applicable to common shareholders	$ (1,416)	$ (1,466)	$ (2,927)	$ (3,015)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.03)	$ (0.04)	$ (0.05)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	67,331	55,056	66,743	55,037

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,922)	$ (3,010)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	65	36
Gain on equipment disposals	(23)
Amortization of other assets	25	26
Accretion of asset retirement obligation	16	15
Share-based compensation	190	240
Changes in operating assets and liabilities:
Accounts receivable, net	85	(261)
Inventory	53	(31)
Prepaid expenses and other current assets	(20)	(24)
Accounts payable and accrued expenses	(195)	(49)
Accrued protocol expense	36	(32)
Accrued radioactive waste disposal	18	(106)
Accrued payroll and related taxes	(35)	27
Accrued vacation	(19)	(15)
Net cash used by operating activities	(2,726)	(3,184)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(225)	(150)
Proceeds from sale of equipment	23
Proceeds from maturity of certificates of deposit	4,418	3,868
Purchases of and interest from certificates of deposit and U.S. Treasury Securities	(8,259)	(3,554)
Net cash (used) provided by investing activities	(4,043)	164
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(11)	(11)
Proceeds from sales of common stock, pursuant to registered direct offering, net	7,381
Proceeds from sales of common stock, pursuant to exercise of options		50
Net cash provided by financing activities	7,370	39
Net increase (decrease) in cash, cash equivalents, and restricted cash	601	(2,981)
Cash, cash equivalents, and restricted cash beginning of period	2,781	6,113
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	3,382	3,132
Reconciliatoin of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	3,201	2,951
Restricted cash	181	181
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	3,382	3,132
Non-cash investing and financing activities:
Warrants issued to placement agent of registered direct offering	$ 163

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2018. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not may 2019 0%.

Note 2 - New Accounting Pronoun

Note 2 - New Accounting Pronouncements	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. New Accounting Pronouncements In May 2014, No. 2014 09 605 10 five first 2019. first 2019 2014 09 not not In February 2016, 2016 02 842 December 15, 2018, first 2020. In August 2016, No. 2016 15 230 eight December 15, 2017, 2016 15 July 1, 2018. 2016 15 not In November 2016, 2016 18, 230 2016 18 no one 2016 18 December 15, 2017 2016 18 first 2019. $181,000 first Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Short-term Investments

Note 3 - Short-term Investments	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Cost-method Investments, Description [Text Block]	3. Short-Term Investments The Company had short-term investments consisting of U.S. Treasury Securities and Certificate of Deposit Account Registry Service (CDARS) as of December 31, 2018 June 30, 2018 Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 Short-term investments held by the Company as of December 31, 2018 June 30, 2018 As of December 31, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year U.S. Treasury Securities $ 2,333 $ 2,334 $ - $ - As of June 30, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ - $ - $ -

Note 4 - Loss Per Share

Note 4 - Loss Per Share	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does not December 31, 2018 2017, not Securities not December 31, 2018 2017, December 31, 2018 2017 Series B preferred stock 59 59 Common stock warrants 6,080 250 Common stock options 3,917 3,295 Total potential dilutive securities 10,056 3,604

Note 5 - Inventory

Note 5 - Inventory	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory Inventory consisted of the following at December 31, 2018 June 30, 2018 ( December 31, June 30, 2018 2018 Raw materials $ 379 $ 371 Work in process 97 96 Finished goods 18 27 Total inventory, current $ 494 $ 494 December 31, June 30, 2018 2018 Enriched barium, non-current $ 234 $ 276 Raw materials, non-current 32 43 Total inventory, non-current $ 266 $ 319 Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 131 4,000 131. December 31, 2018, 2,090 420 12 1,670 12 no third 131

Note 6 - Property and Equipment

Note 6 - Property and Equipment	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following at December 31, 2018 June 30, 2018 ( December 31, June 30, 2018 2018 Land $ 366 $ 366 Equipment 3,778 4,152 Leasehold improvements 4,138 4,136 Other 1 487 328 Property and equipment 8,769 8,982 Less accumulated depreciation (7,298 ) (7,671 ) Property and equipment, net $ 1,471 $ 1,311 1. Plant and equipment, not no December 31, 2018 June 30, 2018 $207,000.

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Share-Based Compensation The following table presents the share-based compensation expense recognized for stock-based options during the three December 31, 2018 2017 Three Months 2018 2017 Cost of product sales $ 10 $ 13 Research and development expenses 18 19 Sales and marketing expenses 22 17 General and administrative expenses 47 29 Total share-based compensation $ 97 $ 78 The following table presents the share-based compensation expense recognized for stock-based options during the six December 31, 2018 2017 Six Months 2018 2017 Cost of product sales $ 20 $ 29 Research and development expenses 36 38 Sales and marketing expenses 44 34 General and administrative expenses 90 67 Total share-based compensation $ 190 $ 168 As of December 31, 2018, $566,000 1.05 A summary of stock options within the Company’s share-based compensation plans as of December 31, 2018 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of December 31, 2018 Options Price Term (Years) Value Outstanding 3,917 $ .68 7.40 $ 10 Vested and expected to vest 3,909 $ .67 7.40 $ 10 Vested and exercisable 2,170 $ .80 6.06 $ 10 There were no 82,810 $0 $0 three December 31, 2018 2017, There were 155,000 no $52,000 $0 three December 31, 2018 2017, There were no three December 31, 2018 2017, There were 32,000 16,875 three December 31, 2018 2017, There were no 82,810 $0 $0 six December 31, 2018 2017, There were 237,500 75,000 $87,000 $33,000 six December 31, 2018 2017, There were 10,000 no six December 31, 2018 2017, There were 70,750 76,541 six December 31, 2018 2017,

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018. December 24, 2018, December 31, 2019 131. 131 May 31, 2019. Research and Development - Collaborative Arrangement On March 13, 2017, November 8, 2016, March 2018 not March 2018, 510 no three six December 31, 2018, 50% December 2018. not not During the three December 31, 2018 2017, $88,000 $58,000, During the six December 31, 2018 2017, $204,000 $205,000, As of December 31, 2018 June 30, 2018, $59,000 $22,000

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value Measurements The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands): Fair Value at December 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,201 $ 3,201 $ - $ - Fair Value at June 30, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,600 $ 2,600 $ - $ - The Company’s cash and cash equivalent instruments are classified within Level 1

Note 10 - Concentrations of Cre

Note 10 - Concentrations of Credit and Other Risks	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	1 0 . Concentrations of Credit and Other Risks One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% Six months ended December 31, December 31, Facility 2018 2017 El Camino Hospital of Los Gatos, & other facilities 1 22.26 % 23.60 % 1 10% one The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.

Note 11 - Shareholders' Equity

Note 11 - Shareholders' Equity	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 1 . Shareholders’ Equity On July 11, 2018, 11,000,000 $0.75, $8.25 $0.75 In a concurrent private placement, the Company sold to each Investor, at no 50% 5,500,000 $0.75 January 11, 2019 January 11, 2024 ( 330,000 $0.9375, The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000 In connection with redomiciling the Company to Delaware, no no 5,000,000 59,065 December 31, 2018.

Note 12 - Contracts With Custom

Note 12 - Contracts With Customers	6 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	1 2 . Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers July 1, 2018 not July 1, 2018 . five 2019 606, not 605, Revenue Recognition We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products that we offer. However, these agreements do not no not not not not not Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic Physicians – direct sales of products. 2. International – direct sales of products. For the three six December 31, 2018 2017, Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not not Returns Generally, we allow returns if not Significant Judgments in the Application of the Guidance in ASC 606 There are no Commissions and Contract Costs We pay and expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not not

Note 3 - Short-term Investmen_2

Note 3 - Short-term Investments (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Cost Method Investments [Table Text Block]	As of December 31, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year U.S. Treasury Securities $ 2,333 $ 2,334 $ - $ - As of June 30, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ - $ - $ -

Note 4 - Loss Per Share (Tables

Note 4 - Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2018 2017 Series B preferred stock 59 59 Common stock warrants 6,080 250 Common stock options 3,917 3,295 Total potential dilutive securities 10,056 3,604

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, June 30, 2018 2018 Raw materials $ 379 $ 371 Work in process 97 96 Finished goods 18 27 Total inventory, current $ 494 $ 494
Schedule of Inventory, Noncurrent [Table Text Block]	December 31, June 30, 2018 2018 Enriched barium, non-current $ 234 $ 276 Raw materials, non-current 32 43 Total inventory, non-current $ 266 $ 319

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, June 30, 2018 2018 Land $ 366 $ 366 Equipment 3,778 4,152 Leasehold improvements 4,138 4,136 Other 1 487 328 Property and equipment 8,769 8,982 Less accumulated depreciation (7,298 ) (7,671 ) Property and equipment, net $ 1,471 $ 1,311

Note 7 - Share-based Compensa_2

Note 7 - Share-based Compensation (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months 2018 2017 Cost of product sales $ 10 $ 13 Research and development expenses 18 19 Sales and marketing expenses 22 17 General and administrative expenses 47 29 Total share-based compensation $ 97 $ 78 Six Months 2018 2017 Cost of product sales $ 20 $ 29 Research and development expenses 36 38 Sales and marketing expenses 44 34 General and administrative expenses 90 67 Total share-based compensation $ 190 $ 168
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of December 31, 2018 Options Price Term (Years) Value Outstanding 3,917 $ .68 7.40 $ 10 Vested and expected to vest 3,909 $ .67 7.40 $ 10 Vested and exercisable 2,170 $ .80 6.06 $ 10

Note 9 - Fair Value Measureme_2

Note 9 - Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value at December 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,201 $ 3,201 $ - $ - Fair Value at June 30, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,600 $ 2,600 $ - $ -

Note 10 - Concentrations of C_2

Note 10 - Concentrations of Credit and Other Risks (Tables)	6 Months Ended
	Dec. 31, 2018
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Six months ended December 31, December 31, Facility 2018 2017 El Camino Hospital of Los Gatos, & other facilities 1 22.26 % 23.60 %

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	6 Months Ended
	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 2 - New Accounting Prono_2

Note 2 - New Accounting Pronouncements (Details Textual) - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 15, 2017	Jun. 30, 2017
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 3,382,000	$ 2,781,000	$ 3,132,000		$ 6,113,000
Accounting Standards Update 2016-18 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance				$ 181,000

Note 3 - Short-Term Investmen_3

Note 3 - Short-Term Investments - Summary of Short- Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2018
Short-term investments (Note 3)	$ 4,667	$ 825
Under 90 Days [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)	2,333
Under 90 Days [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)		825
For 91 Days to Six Months [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)	2,334
For 91 Days to Six Months [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)
Six Months to 1 Year [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)
Six Months to 1 Year [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)
Greater than 1 Year [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)
Greater than 1 Year [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)

Note 4 - Loss Per Share - Antid

Note 4 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive securities (in shares)	10,056	3,604
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	6,080	250
Employee Stock Option [Member]
Antidilutive securities (in shares)	3,917	3,295

Note 5 - Inventory - Current In

Note 5 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2018
Raw materials	$ 379	$ 371
Work in process	97	96
Finished goods	18	27
Total inventory, current	$ 494	$ 494

Note 5 - Inventory - Noncurrent

Note 5 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2018
Total inventory, non-current	$ 266	$ 319
Enriched Barium Inventory [Member]
Total inventory, non-current	234	276
Raw Materials [Member]
Total inventory, non-current	$ 32	$ 43

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 65,000	$ 36,000
Other [Member]
Depreciation, Total	0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Jun. 30, 2018
Property and equipment, gross		$ 8,769	$ 8,982
Less accumulated depreciation		(7,298)	(7,671)
Property and equipment, net		1,471	1,311
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,778	4,152
Leasehold Improvements [Member]
Property and equipment, gross		4,138	4,136
Other [Member]
Property and equipment, gross	[1]	$ 487	$ 328
[1]	Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2018 and June 30, 2018 are costs associated with advance planning and design work on the Company's new production facility of $207,000.

Note 7 - Share-based Compensa_3

Note 7 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 566,000		$ 566,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	82,810	0	82,810
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 0	$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	155,000	0	237,500	75,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 52,000	$ 0	$ 87,000	$ 33,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	0	10,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	32,000	16,875	70,750	76,541

Note 7 - Share-based Compensa_4

Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based compensation	$ 97	$ 78	$ 190	$ 168
Cost of Sales [Member]
Share-based compensation	10	13	20	29
Research and Development Expense [Member]
Share-based compensation	18	19	36	38
Selling and Marketing Expense [Member]
Share-based compensation	22	17	44	34
General and Administrative Expense [Member]
Share-based compensation	$ 47	$ 29	$ 90	$ 67

Note 7 - Share-based Compensa_5

Note 7 - Share-based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Outstanding (in shares) | shares	3,917
Outstanding (in dollars per share) | $ / shares	$ 0.68
Outstanding (Year)	7 years 146 days
Outstanding | $	$ 10
Vested and expected to vest, Options (in shares) | shares	3,909
Vested and expected to vest, Price (in dollars per share) | $ / shares	$ 0.67	[1]
Vested and expected to vest, Life (Year)	7 years 146 days	[2]
Vested and expected to vest, Value | $	$ 10	[3]
Vested and exercisable (in shares) | shares	2,170
Vested and exercisable (in dollars per share) | $ / shares	$ 0.80
Vested and exercisable (Year)	6 years 21 days
Vested and exercisable | $	$ 10
[1]	Weighted average exercise price per share.
[2]	Weighted average remaining contractual life.
[3]	Aggregate intrinsic value (in thousands).

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Purchase Agreement Period	1 year
Research and Development Expense, Total		$ 414,000	$ 340,000	$ 834,000	$ 701,000
Receivables, Net, Current, Total		1,107,000		1,107,000		$ 1,192,000
Collaborative Development Agreement [Member]
Research and Development Expense, Total		88,000	$ 58,000	204,000	$ 205,000
Collaborative Development Agreement [Member] | GammaTile LLC [Member]
Receivables, Net, Current, Total		$ 59,000		$ 59,000		$ 22,000

Note 9 - Fair Value Measureme_3

Note 9 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2018
Cash and cash equivalents	$ 3,201	$ 2,600
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	3,201	2,600
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents

Note 10 - Concentrations of C_3

Note 10 - Concentrations of Credit and Other Risks - Revenue Concentration (Details)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sales Revenue, Goods, Net [Member]
El Camino Hospital of Los Gatos, & other facilities 1	22.26%	23.60%

Note 11 - Shareholders' Equity

Note 11 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 11, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Proceeds from Issuance of Common Stock		$ 7,381
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,830,000
Preferred Stock, Shares Authorized				7,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized		0
Preferred Stock, Shares Outstanding, Ending Balance		0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized		5,000,000		5,000,000
Preferred Stock, Shares Outstanding, Ending Balance		59,065		59,065
Preferred Stock, Shares Issued, Total		59,065		59,065
Series C Preferred Stock [Member]
Preferred Stock, Shares Authorized		0
Preferred Stock, Shares Outstanding, Ending Balance		0
Series D Preferred Stock [Member]
Preferred Stock, Shares Authorized		0
Preferred Stock, Shares Outstanding, Ending Balance		0
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	11,000,000
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 8,250
Payments of Stock Issuance Costs	$ 750
Class of Warrant Or Right, Authorized, Percentage	50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Private Placement [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	330,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375